HSBC Call 350 AMGN 17.01.2025/ DE000HS3XAN9 /
15/11/2024 16:35:24 | Var.-0.150 | Denaro16:38:50 | Lettera16:38:50 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.300EUR | -33.33% | 0.300 Quantità in denaro: 50,000 |
0.320 Quantità in lettera: 50,000 |
Amgen Inc | 350.00 USD | 17/01/2025 | Call |
GlobeNewswire
29/08
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
15/08
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
12/08
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
05/08
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
22/07
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
02/07
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...